Company says recent capital raise extends cash runway through Q2 2027
Nuwellis plans to focus investments on areas with clinical differentiation and commercial opportunity
Company aims to grow recurring revenue and expand in pediatrics and critical care
Overview
Medical technology firm's Q2 net sales rose 14% yr/yr, driven by higher U.S. sales
Gross margin improved to 76% from 56% in prior-year quarter
Company raised $12.7 mln in capital, extending cash runway through Q2 2027
Key Details
Metric
Actual
Q2 Sales
$1.97 mln
Q2 Loss Per Share
$26.64
Q2 Net Loss
$4.83 mln
Q2 Gross Profit
$1.50 mln
Q2 Income from Operations
-$3.17 mln
Q2 Pretax Loss
$4.83 mln
Result Drivers
Higher U.S. circuit and console sales - Co said Q2 revenue growth was driven by increased U.S. circuit and console sales, partially offset by lower technical services, catheter, and international sales
- Gross margin improvement reflected pricing adjustments implemented in 2025, favorable product mix, and transition to contract manufacturing
NUWE•
